Estudios

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer. N Engl J Med 2023; 388:489-498. In patients with peripheral NSCLC with a tumor size of 2 cm or less and pathologically confirmed node-negative disease in the hilar and mediastinal lymph nodes, sublobar resection was not inferior to lobectomy with respect to disease-free survival. Overall survival was similar with the two procedures.

Presenta: Dr. Jorge Verdugo

08 de mayo 2024 16:00hrs / 17:15hrs

Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe Asthma. Thorax 2023;78:868–874. Conclusion A treatment algorithm to adjust OCS using blood eosinophil count and FeNO is feasible in a clinical setting and resulted in a reduced odds of an ED visit. This warrants further study to optimise the use of OCS in the future

Presenta: Dr. Francisco Osses

24 de abril 2024 16:00hrs / 17:15hrs

Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med 2022;386:2071-83. CONCLUSIONS: The risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 ?g of albuterol and 160 ?g of budesonide than with as-needed use of albuterol alone among patients with uncontrolled moderate to-severe asthma who were receiving a wide range of inhaled glucocorticoid-containing maintenance therapies.

Presenta: Dr. Felipe Rozas

15 de abril 2024 16:00hrs / 17:15hrs

Morphine for treatment of cough in idiopathic Pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med 2024 In patients with cough related to idiopathic pulmonary fibrosis, low dose controlled-release morphine significantly reduced objective cough counts over 14 days compared with placebo. Morphine shows promise as an effective treatment to palliate cough in patients with idiopathic pulmonary fibrosis, and longer term studies should be the focus of future research

Presenta: Dr. Miljienko Lolas

10 de abril 2024 16:00hrs / 17:15hrs

Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD A Prospective, Multicenter, Randomized, Open-Label Clinical Trial. CHEST 2021; 160(5):1660-1669.

INTERPRETATION: Personalized dosing of corticosteroids reduces the risk of failure because more patients were provided with a higher initial dose, especially > 60 mg, whereas 40 mg or less was too low in either group.

Presenta: Dra. Paola Zurita

03 de abril 2024 16:00hrs / 17:15hrs